I work in computational biology at a mid-sized pharma company, and our team is under increasing pressure to integrate AI into our early-stage drug discovery pipeline, particularly for target identification and lead compound screening. While the potential is exciting, I'm skeptical of the hype and concerned about the "black box" problem when proposing novel targets to our more traditional medicinal chemists. For researchers who are actively applying AI and machine learning models in a practical drug discovery setting, what have been the most reliable and interpretable approaches for predicting binding affinity or generating synthesizable molecules, and how did you build enough confidence in the model's predictions to justify the significant cost of experimental validation in the wet lab? We need tangible ROI, not just academic benchmarks.
Start simple: treat binding prediction as a classic QSAR problem first. Build a baseline with widely used descriptors (ECFP4 fingerprints, physicochemical properties). Train a simple model (logistic regression for classification, or regression for Ki/Kd predictions) with regularization. Then compare with gradient-boosted trees (XGBoost/LightGBM). Use SHAP or feature importances to interpret which substructures drive affinity. Validate with scaffold/time-split cross-validation and use external test sets. For synthesizability, rely on docking scores plus pose consistency; avoid overfitting.
Uncertainty and data quality matter. Calibrate predicted probabilities, use time-based splitting to simulate prospective predictions, and test generalization across targets. Use ensembles to stabilize predictions and quantify consensus. Establish a lightweight prospective validation plan that links a few top predictions to in vitro assays, even if on a small scale, to estimate real-world hit rates. Consider Bayesian or Gaussian-process-based models to get principled uncertainty estimates.
Interpretable architectures help when you need explanations. Start with a graph neural network (GNN) that can output attention maps, then couple with post-hoc explanations (SHAP-like or atom/fragment-level attributions). If you prefer simpler routes, use linear models with carefully engineered features and display substructure-level importances. Remember: local explanations can be noisy, so validate attributions against known SAR trends and chemist intuition.
Generative design can aid search but must merge with synthesis reality. Use a graph-based generator (VAE/GMVAE or reinforcement learning) constrained by synthetic accessibility scores and explicit retrosynthesis checks (AiZynthFinder, RXN-based planning). Filter candidates with a real retrosynthesis path, expected yield, and available building blocks. Couple the generator with a scoring function that penalizes hard synthesis steps and rewards novelty and medicinal-chemistry plausibility. Create a closed loop: synthesize a few top candidates, feed results back into the model to refine likelihood estimates and rankings.
ROI and governance matter as much as metrics. Track early enrichment, hit rate in your top decile, and time-to-entered-wet-lab stages. Use prospective validation metrics (prospective AUC, calibration) rather than retrospective benchmarks alone. Ensure budget-aware triage, with clear go/no-go gates and a plan for orthogonal validation (biochemical assays, ADMET proxies) before heavy chemistry investments. Build a data provenance plan and require explainability trials before high-stakes decisions.
If you’d like, share a rough outline of your data (data volume, targets, assay types) and I’ll sketch a concrete 6–8 week pilot plan, including a lightweight evaluation rubric and a small, risk-adjusted budget.